Walleye Capital’s Takeda Pharmaceutical TAK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$248K Sell
15,469
-245,348
-94% -$4.06M ﹤0.01% 3330
2026
Q1
$4.83M Buy
260,817
+177,734
+214% +$3.12M 0.02% 824
2025
Q4
$1.3M Sell
83,083
-138,439
-62% -$1.98M ﹤0.01% 2223
2025
Q3
$3.24M Buy
221,522
+189,742
+597% +$2.82M 0.01% 1216
2025
Q2
$491K Buy
+31,780
New +$470K ﹤0.01% 2646
2024
Q1
Sell
-22,460
Closed -$321K 5884
2023
Q4
$321K Sell
22,460
-4,968
-18% -$70.5K ﹤0.01% 3323
2023
Q3
$424K Buy
+27,428
New +$425K ﹤0.01% 2935

Other funds holding TAK

Walleye Capital's TAK Position: Q2 2026 in Review

Walleye Capital reduced its Takeda Pharmaceutical (TAK) stake by 94% in Q2 2026, selling an estimated $4.06M and leaving 15,469 shares worth $248K. The position accounts for ﹤0.01% of the portfolio, ranked #3330.

Walleye Capital first reported a position in TAK in Q3 2023 and has held it in 7 quarters since. The position peaked at $4.83M in Q1 2026. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Walleye Capital held 15,469 shares of Takeda Pharmaceutical worth $248K as of Q2 2026.
  • Walleye Capital sold 245,348 Takeda Pharmaceutical shares in Q2 2026, an estimated $4.06M.
  • Takeda Pharmaceutical made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3330 holding.
  • Walleye Capital first reported a position in Takeda Pharmaceutical in Q3 2023 and has held it in 7 quarters since.
  • Walleye Capital's Takeda Pharmaceutical position peaked at $4.83M in Q1 2026.
  • 378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.